Staar Surgical Company Stock News

STAAR Surgical (NASDAQ:STAA) CEO Caren L. Mason sold 35,000 shares of the companys stock in a transaction dated Thursday, November 18th. The shares were sold at an average price of $113.83, for a total transaction of $3,984,050.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. STAAR []

STAAR Surgical (NASDAQ:STAA) CEO Caren L. Mason sold 35,000 shares of the stock in a transaction that occurred on Tuesday, November 16th. The stock was sold at an average price of $114.20, for a total transaction of $3,997,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. []

STAAR Surgical (NASDAQ:STAA) CEO Caren L. Mason sold 35,000 shares of the companys stock in a transaction dated Thursday, November 18th. The stock was sold at an average price of $113.83, for a total transaction of $3,984,050.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. []

STAAR Surgical (NASDAQ:STAA) has been given an average rating of Hold by the six analysts that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokers that have issued []

Brokerages expect STAAR Surgical (NASDAQ:STAA) to announce $0.16 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for STAAR Surgicals earnings, with estimates ranging from $0.14 to $0.17. STAAR Surgical posted earnings of $0.14 per share in the same quarter last year, which indicates a positive []

STAAR Surgical Company (STAA) CEO Caren Mason on Q3 2021 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 31.25% and 1.13%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

STAAR Surgical (STAA) has been an excellent investment so far. Growth prospects for this company are bright over the long run.

Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.

Staar Surgical (STAA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

STAAR Surgical Company (NASDAQ: STAA) Q2 sales increased 77% Y/Y to $62.4 million and up 23% on a sequential basis, beating the consensus of $52.56 million. The growth was attributable to global IC

STAAR Surgical's (STAA) CEO Caren Mason on Q2 2021 Results - Earnings Call Transcript

Staar Surgical (STAA) delivered earnings and revenue surprises of 237.50% and 17.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Their business models are timeless, and their revenue is rising.

STAAR Surgical (STAA) has been struggling lately, but the selling pressure may be coming to an end soon.